Biofrontera Inc. to Report Second Quarter 2026 Financial Results on August 13, 2026
Globe Newswire•05/08/2026•16:15 ET
0
Whiz Insights
WOBURN, Mass., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Biofrontera Inc. (NASDAQ: BFRI) ("Biofrontera" or the "Company"), a U.S. specialty dermatology company commercializing Ameluz(®) (aminolevulinic acid hydrochloride) Gel, 10% with the BF-RhodoLED(®) lamp for photodynamic therapy (PDT) of actinic keratosis, today announced that it will report financial results for the second quarter ended June 30, 2026 before the market opens on Thursday, August 13, 2026.
Management will host a conference call and webcast the same day at 10:00 a.m. Eastern Time to discuss the results and provide a business update.
Get started
Create a free account to read the full story.